Market Cap
US$2.7b
Last Updated
2020/02/17 01:05 UTC
Data Sources
Company Financials +
Executive Summary
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Excellent balance sheet and slightly overvalued.
Similar Companies
Share Price & News
How has uniQure's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: QURE has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
0.6%
QURE
0.06%
US Biotechs
1.8%
US Market
1 Year Return
68.7%
QURE
11.0%
US Biotechs
20.1%
US Market
Return vs Industry: QURE exceeded the US Biotechs industry which returned 11% over the past year.
Return vs Market: QURE exceeded the US Market which returned 20.1% over the past year.
Shareholder returns
| QURE | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.6% | 0.06% | 1.8% |
| 30 Day | -6.4% | 0.5% | 1.4% |
| 90 Day | 14.9% | 10.4% | 8.8% |
| 1 Year | 68.7%68.7% | 12.0%11.0% | 22.7%20.1% |
| 3 Year | 901.4%901.4% | 16.8%13.6% | 50.1%40.4% |
| 5 Year | 201.0%201.0% | -1.2%-6.0% | 72.9%53.9% |
Price Volatility Vs. Market
How volatile is uniQure's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
How Many uniQure N.V. (NASDAQ:QURE) Shares Have Insiders Sold, In The Last Year?1 month ago | Simply Wall St
Does The uniQure N.V. (NASDAQ:QURE) Share Price Tend To Follow The Market?2 months ago | Simply Wall St
Investors Who Bought uniQure (NASDAQ:QURE) Shares Three Years Ago Are Now Up 1121%Valuation
Is uniQure undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: QURE ($63.19) is trading below our estimate of fair value ($204.32)
Significantly Below Fair Value: QURE is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: QURE is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: QURE is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate QURE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: QURE is overvalued based on its PB Ratio (7.4x) compared to the US Biotechs industry average (3.2x).
Next Steps
Future Growth
How is uniQure forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
40.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: QURE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: QURE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: QURE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: QURE's revenue (63.2% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: QURE's revenue (63.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: QURE is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has uniQure performed over the past 5 years?
-11.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: QURE is currently unprofitable.
Growing Profit Margin: QURE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: QURE is unprofitable, and losses have increased over the past 5 years at a rate of -11.4% per year.
Accelerating Growth: Unable to compare QURE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: QURE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (66.2%).
Return on Equity
High ROE: QURE has a negative Return on Equity (-30.4%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is uniQure's financial position?
Financial Position Analysis
Short Term Liabilities: QURE's short term assets ($407.6M) exceed its short term liabilities ($28.4M).
Long Term Liabilities: QURE's short term assets ($407.6M) exceed its long term liabilities ($92.9M).
Debt to Equity History and Analysis
Debt Level: QURE's debt to equity ratio (10.3%) is considered satisfactory.
Reducing Debt: QURE's debt to equity ratio has reduced from 31.4% to 10.3% over the past 5 years.
Balance Sheet
Inventory Level: QURE has a low level of unsold assets or inventory.
Debt Coverage by Assets: QURE's debt is covered by short term assets (assets are 11.3x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: QURE has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if QURE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is uniQure's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate QURE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate QURE's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if QURE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if QURE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of QURE's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.8yrs
Average management tenure
CEO
Matt Kapusta (47yo)
3.2yrs
Tenure
US$4,095,328
Compensation
Mr. Matthew Craig Kapusta, also known as Matt, has been the Chief Executive Officer of uniQure N.V. since December 19, 2016 and serves as its Chief Financial Officer. Mr. Kapusta served as a Chief Financia ...
CEO Compensation Analysis
Compensation vs Market: Matt's total compensation ($USD4.10M) is about average for companies of similar size in the US market ($USD4.88M).
Compensation vs Earnings: Matt's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, CFO & Executive Director | 3.2yrs | US$4.10m | 0.62% $16.7m | |
| Executive Vice President of Operations | 0.5yrs | US$945.14k | 0.058% $1.6m | |
| Senior Vice President of Investor Relations & Communication | 3.7yrs | US$1.22m | 0.16% $4.4m | |
| Chief Business Officer | 3.6yrs | US$1.32m | 0.21% $5.8m | |
| Chief Medical Officer & Executive Director | 1.7yrs | US$19.99k | 0.016% $425.2k | |
| Co-Founder | 0yrs | US$129.40k | 0.065% $1.8m | |
| Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | 5.5yrs | no data | no data | |
| Chief Accounting Officer | 2.5yrs | no data | 0.099% $2.7m | |
| Chief Legal Officer | 1.9yrs | no data | no data | |
| Business Development Director | 11.7yrs | no data | no data |
2.8yrs
Average Tenure
52.5yo
Average Age
Experienced Management: QURE's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, CFO & Executive Director | 3.2yrs | US$4.10m | 0.62% $16.7m | |
| Chief Medical Officer & Executive Director | 1.7yrs | US$19.99k | 0.016% $425.2k | |
| Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | 5.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 0yrs | no data | no data | |
| Chairman | 3.4yrs | US$254.42k | 0.014% $379.6k | |
| Member of Scientific Advisory Board | 0yrs | no data | no data | |
| Member of Scientific Advisory Board | 0yrs | no data | no data | |
| Member of Scientific Advisory Board | 0yrs | no data | no data | |
| Non-Executive Director | 2.4yrs | US$204.32k | 0.014% $379.6k | |
| Non-Executive Director | 2.4yrs | US$214.06k | 0.014% $379.6k |
2.9yrs
Average Tenure
57yo
Average Age
Experienced Board: QURE's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: QURE insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.5%.
Top Shareholders
Company Information
uniQure N.V.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: uniQure N.V.
- Ticker: QURE
- Exchange: NasdaqGS
- Founded: 1998
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.700b
- Shares outstanding: 42.72m
- Website: https://www.uniqure.com
Number of Employees
Location
- uniQure N.V.
- Paasheuvelweg 25a
- Amsterdam
- Noord-Holland
- 1105 BP
- Netherlands
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| QURE | NasdaqGS (Nasdaq Global Select) | Yes | Ordinary Shares | US | USD | Feb 2014 |
| 0EE0 | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | USD | Feb 2014 |
Biography
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington’s disease; and AMT-126 for the treatment of heart failure. In addition, the company engages in developing AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment hemophilia A; AMT-190, a differentiated gene therapy for the treatment of Fabry disease; and AMT-150, a gene therapy for SCA3, a central nervous system disorder. The company has collaboration and license agreements with Bristol Myers-Squibb; 4D Molecular Therapeutics, LLC; and Synpromics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/17 01:05 |
| End of Day Share Price | 2020/02/14 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.